Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management
Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...
Drug
AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results
AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...
Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706
Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...
Eisai’s Lemborexant Sleep Aid Lemborexant Filed for NMPA Approval in China
The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523)...
Joincare Pharmaceutical’s Partner Fermion Gets NMPA Green Light for Pain Drug Clinical Study
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical company, has announced that...
GSK Secures Second Indication Approval for Nucala in China for Severe Eosinophilic Asthma
GSK plc (NYSE: GSK) has received approval for a second indication in China for its...
Eli Lilly Secures NMPA Approval for Emgality as Preventive Migraine Treatment in China
Eli Lilly (NYSE: LLY) has received marketing approval from the National Medical Products Administration (NMPA)...
GenFleet’s SLS009 Receives Fast-Track and Orphan Drug Designations from U.S. FDA for Lymphoma and Leukemia
Shanghai-based biotech GenFleet Therapeutics announced that its CDK9 inhibitor, SLS009 (GFH009), has received fast-track and...
Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China
Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...
Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration
The US Food and Drug Administration (FDA) has accepted for priority review a filing from...
AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU
AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...
OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study
OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...
MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females
Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...
Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies
The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...
3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment
3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...
Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China
Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...
Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments
The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...
Thederma’s TAP-1503 Cream Receives Priority Review Status for Pediatric Atopic Dermatitis Treatment in China
The Center for Drug Evaluation (CDE) website has indicated that China-based Thederma’s TAP-1503 cream is...
Innovent Biologics’ Mazdutide Achieves Positive Results in Phase III Clinical Trial for Overweight or Obesity
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
Abbisko Therapeutics’ Pimicotinib Earns Orphan Drug Designation from EMA for TGCT Treatment
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced that it has...